MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$392,833,000
Net Income
-$128,630,000
Net Profit Margin
-32.74%
EPS
-$1.69
Unit: Dollar
Revenue Breakdown
Segment adjusted income (loss) f...
Cost of revenues-generic pharmac...
Selling and marketing-branded ph...
Others
Revenue Breakdown
Xiaflex
Generic pharmaceuticals segment
Other sterile injectables
Others
Revenue Breakdown
Total revenues, net-branded phar...
Total revenues, net-generic phar...
Total revenues, net-sterile inje...
Total revenues, net-internationa...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2025-03-31
2024-09-30
2024-06-30
Total revenues, net
392,833,000
426,506,000
-
Other expense, net
-1,028,000
1,193,000
-
Selling, general and administrative
149,041,000
148,322,000
-
Research and development
31,634,000
20,190,000
-
Acquired in-process research and development
2,536,000
1,750,000
-
Interest expense, net
-52,670,000
-62,727,000
-
Litigation-related and other contingencies, net
-320,000
-200,000
-
Cost of revenues
295,403,000
448,324,000
-
Acquisition-related and integration items, net
1,015,000
1,773,000
-
Loss from continuing operations before income tax
-140,814,000
-255,587,000
-
Income tax (benefit) expense
-12,184,000
-22,811,000
-
Loss from continuing operations
-128,630,000
-232,776,000
0
Net loss
-128,630,000
-232,776,000
-148,776,000
Basic EPS
-1.69
-3.06
-
Diluted EPS
-1.69
-3.06
-
Basic Average Shares
76,211,000
76,156,000
-
Diluted Average Shares
76,211,000
76,156,000
-
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
3
Net loss
-$128,630,000
Loss from continuing
operations
-$128,630,000
Income tax (benefit)
expense
-$12,184,000
Segment adjusted income
(loss) from operations...
$112,237,000
Cost of
revenues-generic...
$70,760,000
Selling and
marketing-branded...
$60,183,000
Cost of
revenues-sterile injectables...
$56,292,000
Segment adjusted income
(loss) from operations...
$21,707,000
Adjusted research and
development-sterile injectables...
$17,894,000
Cost of
revenues-branded...
$16,781,000
Adjusted research and
development-branded...
$11,739,000
General and
administrative-branded...
$8,551,000
Cost of
revenues-international...
$6,141,000
Selling and
marketing-sterile injectables...
$3,850,000
General and
administrative-sterile injectables...
$3,670,000
General and
administrative-generic...
$2,984,000
General and
administrative-international...
$2,938,000
Selling and
marketing-international...
$2,486,000
Adjusted research and
development-generic...
$2,001,000
Selling and
marketing-generic...
$1,632,000
Segment adjusted income
(loss) from operations...
$1,422,000
Loss from continuing
operations before income...
-$140,814,000
Total revenues, net
$392,833,000
Segment adjusted income
(loss) from operations...
-$10,435,000
Cost of revenues
$295,403,000
Selling, general and
administrative
$149,041,000
Interest expense, net
-$52,670,000
Research and development
$31,634,000
Acquired in-process
research and development
$2,536,000
Other expense, net
-$1,028,000
Acquisition-related and integration
items, net
$1,015,000
Litigation-related and other
contingencies, net
-$320,000
Buy us a coffee
Endo, Inc. (NDOI)
Endo, Inc. (NDOI)